Business
Phio Pharmaceuticals Announces Upcoming Presentation at ASGCT's 2024 Advancing Gene + Cell Therapies for Cancer Conference
Marlborough, Massachusetts--(Newsfile Corp. - October 1, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical stage biotechnology company whose
About this update from Phio Pharmaceuticals Corp.
[{"type":"text","content":"Marlborough, Massachusetts--(Newsfile Corp. - October 1, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical stage biotechnology company whose proprietary INTASYL® siRNA gene silencing technology is designed to make immune cells more effective in killing tumor cells, today announced it is presenting data about its INTASYL compound PH-894 at the American Society of Gene & Cell Therapy's (ASGCT's) 2024 Advancing Gene + Cell Therapies for Cancer conference. The conference will take place October 16-17, 2024, virtually and at the Wyndham Hotel, Philadelphia Historic District, 400 Arch Street, Philadelphia, PA.\nPhio's presentation will focus on how its INTASYL compound PH-894 precisely silences BRD4 and enhances activation and proliferation of Natural Killer (NK) cells for Adoptive Cell Therapy (ACT).\nPresentation Details are as follows:\n\n\n\nAbstract Title:\nINTASYL PH-894: Targeting BRD4 to Enhance NK Cell-Based Immunotherapy \n\n\nPresenting Author:\nMelissa Maxwell\n\n\nDate:\nOctober 16, 2024\n\n\nTime:\n8 a.m. - 6:45 p.m. ET\n\n\nRoom: \nFDR Ballroom\n\n\n\n \nAbout Phio Pharmaceuticals Corp.\nPhio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage biotechnology company focused on silencing specific genes using its proprietary INTASYL siRNA technology. In non-systemic applications, INTASYL can target and silence virtually any gene with high specificity across a wide range of tissue types. INTASYL is primarily designed to enhance the ability of immune cells to kill tumor cells and can play a key role in improving adoptive cell therapy. Notably, INTASYL is the only self-delivering RNAi technology, in that does not require specialized formulations or drug delivery systems.\nFor additional information, visit the Company's website, www.phiopharma.com.\nForward-Looking Statements\nThis press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as \"intends,\" \"believes,\" \"anticipates,\" \"indicates,\" \"plans,\" \"expects,\" \"suggests,\" \"may,\" \"would,\" \"should,\" \"potential,\" \"designed to,\" \"will,\" \"ongoing,\" \"estimate,\" \"forecast,\" \"target,\" \"predict,\" \"could\" and similar references, although not all forward-looking statements contain these words. These statemen...